The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma

Background. Transarterial chemoembolization (TACE) combined with sorafenib (TACE-S) or apatinib (TACE-A) is used in the treatment of hepatocellular carcinoma (HCC). However, to date, no study has compared the efficacy and safety of both treatments. The objective of this study was to compare the effi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lei Chen, Tao Sun, Linxia Wu, Weihua Zhang, Yanqiao Ren, Dongqiao Xiang, Bin Liang, Chuansheng Zheng
Formato: article
Lenguaje:EN
Publicado: Hindawi Limited 2021
Materias:
Acceso en línea:https://doaj.org/article/7c376d1b25a64b63bedd576fcdbef0c6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:7c376d1b25a64b63bedd576fcdbef0c6
record_format dspace
spelling oai:doaj.org-article:7c376d1b25a64b63bedd576fcdbef0c62021-11-29T00:55:45ZThe Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma1687-846910.1155/2021/8169012https://doaj.org/article/7c376d1b25a64b63bedd576fcdbef0c62021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/8169012https://doaj.org/toc/1687-8469Background. Transarterial chemoembolization (TACE) combined with sorafenib (TACE-S) or apatinib (TACE-A) is used in the treatment of hepatocellular carcinoma (HCC). However, to date, no study has compared the efficacy and safety of both treatments. The objective of this study was to compare the efficacy and safety of patients with advanced HCC who received either TACE-S or TACE-A. Methods. 193 patients with advanced HCC were included in the study between June 2015 and December 2019. Propensity score matching (PSM) analysis was used in the study to reduce selection bias. Results. Before PSM, the median overall survival (mOS) and median progression-free survival (mPFS) of patients treated with TACE-S were not significantly longer than in patients treated with TACE-A (P=0.703, P=0.514). TACE-A did not increase the mortality risk compared with TACE-S in the first 12 months (HR: 1.255, 95%CI: 0.796–1.978, P=0.329) or after the 12-month mark (HR: 0.832, 95%CI: 0.482–1.436, p=0.508). Similarly, TACE-A did not increase the tumor recurrence risk relative to TACE-S in the first 12 months (HR: 1.054, 95%CI: 0.744–1.493, P=0.767) or after the 12-month mark (HR: 1.730, 95%CI: 0.592–5.049, P=0.316). The subgroups analysis showed that TACE-A did not increase mortality risk or tumor recurrence risk relative to TACE-S. After PSM, similar results were presented. The III and IV stage adverse events in the TACE-A group were similar to those in the TACE-S group before PSM. Conclusions. Patients with advanced hepatocellular carcinoma could get similar survival benefits from treatment with either transarterial chemoembolization plus apatinib or transarterial chemoembolization plus sorafenib.Lei ChenTao SunLinxia WuWeihua ZhangYanqiao RenDongqiao XiangBin LiangChuansheng ZhengHindawi LimitedarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJournal of Oncology, Vol 2021 (2021)
institution DOAJ
collection DOAJ
language EN
topic Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
spellingShingle Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Lei Chen
Tao Sun
Linxia Wu
Weihua Zhang
Yanqiao Ren
Dongqiao Xiang
Bin Liang
Chuansheng Zheng
The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
description Background. Transarterial chemoembolization (TACE) combined with sorafenib (TACE-S) or apatinib (TACE-A) is used in the treatment of hepatocellular carcinoma (HCC). However, to date, no study has compared the efficacy and safety of both treatments. The objective of this study was to compare the efficacy and safety of patients with advanced HCC who received either TACE-S or TACE-A. Methods. 193 patients with advanced HCC were included in the study between June 2015 and December 2019. Propensity score matching (PSM) analysis was used in the study to reduce selection bias. Results. Before PSM, the median overall survival (mOS) and median progression-free survival (mPFS) of patients treated with TACE-S were not significantly longer than in patients treated with TACE-A (P=0.703, P=0.514). TACE-A did not increase the mortality risk compared with TACE-S in the first 12 months (HR: 1.255, 95%CI: 0.796–1.978, P=0.329) or after the 12-month mark (HR: 0.832, 95%CI: 0.482–1.436, p=0.508). Similarly, TACE-A did not increase the tumor recurrence risk relative to TACE-S in the first 12 months (HR: 1.054, 95%CI: 0.744–1.493, P=0.767) or after the 12-month mark (HR: 1.730, 95%CI: 0.592–5.049, P=0.316). The subgroups analysis showed that TACE-A did not increase mortality risk or tumor recurrence risk relative to TACE-S. After PSM, similar results were presented. The III and IV stage adverse events in the TACE-A group were similar to those in the TACE-S group before PSM. Conclusions. Patients with advanced hepatocellular carcinoma could get similar survival benefits from treatment with either transarterial chemoembolization plus apatinib or transarterial chemoembolization plus sorafenib.
format article
author Lei Chen
Tao Sun
Linxia Wu
Weihua Zhang
Yanqiao Ren
Dongqiao Xiang
Bin Liang
Chuansheng Zheng
author_facet Lei Chen
Tao Sun
Linxia Wu
Weihua Zhang
Yanqiao Ren
Dongqiao Xiang
Bin Liang
Chuansheng Zheng
author_sort Lei Chen
title The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
title_short The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
title_full The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
title_fullStr The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
title_full_unstemmed The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
title_sort efficacy of transarterial chemoembolization plus apatinib or sorafenib in the treatment of advanced hepatocellular carcinoma
publisher Hindawi Limited
publishDate 2021
url https://doaj.org/article/7c376d1b25a64b63bedd576fcdbef0c6
work_keys_str_mv AT leichen theefficacyoftransarterialchemoembolizationplusapatiniborsorafenibinthetreatmentofadvancedhepatocellularcarcinoma
AT taosun theefficacyoftransarterialchemoembolizationplusapatiniborsorafenibinthetreatmentofadvancedhepatocellularcarcinoma
AT linxiawu theefficacyoftransarterialchemoembolizationplusapatiniborsorafenibinthetreatmentofadvancedhepatocellularcarcinoma
AT weihuazhang theefficacyoftransarterialchemoembolizationplusapatiniborsorafenibinthetreatmentofadvancedhepatocellularcarcinoma
AT yanqiaoren theefficacyoftransarterialchemoembolizationplusapatiniborsorafenibinthetreatmentofadvancedhepatocellularcarcinoma
AT dongqiaoxiang theefficacyoftransarterialchemoembolizationplusapatiniborsorafenibinthetreatmentofadvancedhepatocellularcarcinoma
AT binliang theefficacyoftransarterialchemoembolizationplusapatiniborsorafenibinthetreatmentofadvancedhepatocellularcarcinoma
AT chuanshengzheng theefficacyoftransarterialchemoembolizationplusapatiniborsorafenibinthetreatmentofadvancedhepatocellularcarcinoma
AT leichen efficacyoftransarterialchemoembolizationplusapatiniborsorafenibinthetreatmentofadvancedhepatocellularcarcinoma
AT taosun efficacyoftransarterialchemoembolizationplusapatiniborsorafenibinthetreatmentofadvancedhepatocellularcarcinoma
AT linxiawu efficacyoftransarterialchemoembolizationplusapatiniborsorafenibinthetreatmentofadvancedhepatocellularcarcinoma
AT weihuazhang efficacyoftransarterialchemoembolizationplusapatiniborsorafenibinthetreatmentofadvancedhepatocellularcarcinoma
AT yanqiaoren efficacyoftransarterialchemoembolizationplusapatiniborsorafenibinthetreatmentofadvancedhepatocellularcarcinoma
AT dongqiaoxiang efficacyoftransarterialchemoembolizationplusapatiniborsorafenibinthetreatmentofadvancedhepatocellularcarcinoma
AT binliang efficacyoftransarterialchemoembolizationplusapatiniborsorafenibinthetreatmentofadvancedhepatocellularcarcinoma
AT chuanshengzheng efficacyoftransarterialchemoembolizationplusapatiniborsorafenibinthetreatmentofadvancedhepatocellularcarcinoma
_version_ 1718407778954903552